C6orf225 Inhibitors
Chemical inhibitors of C6orf225 encompass a variety of compounds that target specific signaling pathways and kinases involved in the regulation and activity of this protein. Staurosporine, a potent kinase inhibitor, can disrupt the phosphorylation processes vital to C6orf225's function by binding to the ATP-binding sites of kinases within its signaling pathways. Similarly, the PI3K inhibitors Wortmannin and LY294002 can impede the PI3K/AKT/mTOR signaling pathway, leading to a reduction in the activation and subsequent phosphorylation of proteins such as C6orf225. Rapamycin specifically inhibits mTOR, a central component of the pathway responsible for protein synthesis and function, thus also affecting the activity of C6orf225.
Other inhibitors target different aspects of cellular signaling that can influence C6orf225. PD98059 and U0126, both MEK inhibitors, can prevent the activation of the ERK/MAPK signaling pathway, which is fundamental to numerous cellular activities. By inhibiting MEK, these compounds can reduce the activity of proteins that operate within this cascade, including C6orf225. The JNK signaling pathway, which can be suppressed by the JNK inhibitor SP600125, and the p38 MAPK signaling pathway, targeted by SB203580, are critical for stress responses and cytokine production. Inhibition of these pathways can result in the decreased function of relevant proteins like C6orf225. Moreover, Dasatinib and PP2 inhibit Src family kinases and Abl, which could decrease the function of proteins regulated by these kinases, including C6orf225. Finally, inhibitors such as Bisindolylmaleimide I and Go6983 target protein kinase C (PKC), leading to a reduction in PKC-mediated signaling pathways. As PKC is essential for the phosphorylation and activity of many proteins, the inhibition by these compounds can lead to decreased functionality of proteins like C6orf225 that may be regulated by PKC-dependent phosphorylation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. It inhibits C6orf225 by targeting the ATP-binding site of kinases that are involved in the signaling pathways which C6orf225 is part of, leading to a decrease in the phosphorylation events necessary for C6orf225's activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. By inhibiting mTOR, it disrupts downstream signaling pathways necessary for the activity of C6orf225, as mTOR signaling is crucial for the protein synthesis and function of many cellular proteins, including C6orf225. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor which by inhibiting PI3K, it would impede the PI3K/AKT/mTOR signaling pathway, thereby inhibiting the phosphorylation and activation of proteins that are downstream in this pathway, including potentially C6orf225. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin. By inhibiting PI3K, LY294002 prevents the activation of AKT and subsequent mTOR signaling, leading to inhibited phosphorylation of several proteins, which may include C6orf225, depending on its reliance on this pathway for activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, and by inhibiting MEK, it prevents the activation of ERK/MAPK signaling pathway. As ERK/MAPK is involved in the regulation of a wide range of cellular activities, inhibition by PD98059 could lead to decreased function of proteins like C6orf225 that are part of this signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor and functions similarly to PD98059. By prohibiting MEK, U0126 would inhibit ERK activation and therefore could hinder the function of proteins like C6orf225 that are dependent on the MEK/ERK pathway for their activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. By inhibiting JNK, it can suppress the JNK signaling pathway. The JNK pathway is involved in a wide array of cellular functions, and inhibition by SP600125 could lead to functional inhibition of proteins, such as C6orf225, that rely on JNK signaling for their activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It inhibits the p38 MAPK signaling pathway, which is implicated in stress responses, cytokine production, and cell cycle regulation. Inhibition by SB203580 could reduce the functional activity of proteins like C6orf225 that are regulated through p38 MAPK signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase and Abl inhibitor. It inhibits Src family kinases and Abl, which are part of signaling pathways that regulate various cellular processes. Inhibition by Dasatinib could decrease the function of proteins such as C6orf225 that are regulated by Src family kinase activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. By inhibiting Src family kinases, PP2 would disrupt signaling pathways involving these kinases. If C6orf225 activity is regulated by Src family kinase signaling, PP2 would inhibit its function. | ||||||